DDrare: Database of Drug Development for Rare Diseases

552-02 (DrugBank: -)

2 diseases

ID	Disease name (Link within this page)	Number of trials
53	Sjogren syndrome	1
299	Cystic fibrosis	1

53. Sjogren syndrome [ 234 clinical trials, 270 drugs, (DrugBank: 85 drugs), 49 drug target genes, 174 drug target pathways]

Searched query = "Sjogren syndrome", "Sjögren syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 234 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00852839 (ClinicalTrials.gov)	February 2009	26/2/2009	A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome	A Randomized, Double-Blind, Vehicle-Controlled, Parallel Arm Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome	Dry Mouth Associated With Sjogren's Syndrome;Xerostomia	Drug: Placebo;Drug: 552-02	Parion Sciences	NULL	Completed	18 Years	80 Years	All	140	Phase 2	United States

299. Cystic fibrosis [ 1,592 clinical trials, 1,539 drugs, (DrugBank: 255 drugs), 81 drug target genes, 162 drug target pathways]

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 1,592 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00274313 (ClinicalTrials.gov)	January 2006	6/1/2006	Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients	A Study of the Safety and Pharmacokinetics of 552-02 Following 14 Days of Dosing By Inhalation in Patients With Cystic Fibrosis	Cystic Fibrosis	Drug: 552-02	Parion Sciences	NULL	Completed	14 Years	N/A	Both	40	Phase 1;Phase 2	United States